Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Molecular Markers: The More You Seek, the More You Find
Author
Howard (Jack) West, MD

Here's a video I just did in response to my recent spate of molecular marker studies I've sent in the last 4-6 weeks that have come back with quite a few positive results for an EGFR mutation or ALK rearrangement, as well as one patient positive for a ROS1 rearrangement.  For each of these patients, the results have had a major impact in the opportunity for them to receive an oral therapy with a high probability of response, and in a few cases, we've already seen a significant improvement.

The reason I made this video was that while I haven't found these mutations in a long-time smoker with a squamous cancer, I have been impressed by the range of patients in whom I've seen an "actionable" mutation.   Though some of the mutations were in never-smokers with an adenocarcinoma, quite a few have been in patients with a very significant smoking history and/or a poorly differentiated tumor.   And I've seen mutations more frequently than I might have anticipated.

I just had a long conversation with Dr. Horton, the pathologist at my institution who has a particular focus on lung cancer and who is very current on molecular testing.  We were discussing that we are living through some significant changes, in real time, that are still playing out.  Are we going to see the same patterns of which patients have mutations as we expand the tested population from few dozen in the initial reports to hundreds and thousands?  Are the growing number of places doing testing conducting these tests in the same way, so that the patients who are reported as ALK positive or EGFR mutation positive have the same high rate of response, or might we see a broader range of positivity with a lower response rate because it's diluted?  Are the general "rules" about mutations being mutually exclusive or being extremely infrequent in squamous histology going to hold true as we test more patients?

[powerpress]

As I mention in the video, it can be difficult to change your view, but I think that's the appropriate action to take if new information coming should lead to a change.  We don't want to be wishy-washy, but I think it's also a mistake to tenaciously hold onto perspectives that might have been appropriate based on the information available previously, but not necessarily as new information comes in.  I am happy that my views on molecular vs. clinical factors predicting response to oral EGFR inhibitors changed with the results from the IPASS trial, and as we learn more about molecular oncology, we should all recognize that the story is still being written, and that we need to be open to changing our views on the basis of new knowledge we're gaining in real time.

Next Previous link

Previous PostNext Post

Related Content

Image
Clinical Trials Storytelling 2025
Article
GRACE is pleased to introduce three amazing individuals participating in the 2024-25 GRACE Clinical Trials Experiences Storytelling Program
Article
Imagine your body's defense system, the lymphatic system, suddenly turning against you. This is the reality for those facing lymphoma, a cancer of the immune system's crucial network. This article delves into the complexities of lymphoma, exploring its various forms, from the aggressive to the indolent, and examining the latest breakthroughs in treatment, including the groundbreaking POLARIX trial and cutting-edge therapies for relapsed cases. Whether you're a patient, a loved one, or simply curious about this complex disease, this comprehensive overview will provide valuable insights into the current state of lymphoma care and the promising future of research.
Image
Melanoma Video Library
Video
In these videos, Dr. Autumn Starnes gives an overview of melanoma's prevalence and risk factors. She also discusses the ABCDE method of self-screening for skin cancer, common misconceptions regarding people of color, and melanoma, and how a person can lower their risk of developing melanoma, among other relevant topics regarding melanoma.  To watch the complete playlist, click here. 

Forum Discussions

Can SCLC also be treated with targeted therapy?

Hi amitchouhan,

Welcome to Grace. At this time, there aren't any targeted therapies to treat SCLC, but there are new treatments. Check out our latest OncTalk webinar from December. The last...

I was searching for this, Thank you so much for the info.

Glad to help.  FYI, I just edited the link, which has the agenda and links to oncologists' bios. Plus, the link is also on our home page, https://cancergrace.org/

Hope to see...

Recent Comments

JOIN THE CONVERSATION
Glad to help.  FYI, I just…
By JanineT GRACE … on
I was searching for this,…
By LilahStapleton on
Hi and welcome.  I'm sorry…
By JanineT GRACE … on
Hi amitchouhan,

Welcome to…
By JanineT GRACE … on